Multiple gene polymorphisms and warfarin sensitivity

European Journal of Clinical Pharmacology

Volumn 62, Issue 10, 2006, Pages 881-883

  Shikata, Eriko ^a   Ieiri, Ichiro ^a,c   Ishiguro, Shingo ^b   Takane, Hiroshi ^a   Ohgi, Shigetsugu ^b   Otsubo, Kenji ^a  

^a TOTTORI UNIVERSITY   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 7; CYTOCHROME P450 2C9; VITAMIN K DEPENDENT CARBOXYLASE; WARFARIN;

ALLELE; BLEEDING; DNA POLYMORPHISM; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG SENSITIVITY; DRUG UPTAKE; ETHNIC DIFFERENCE; ETHNOLOGY; GENE AMPLIFICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HOMOZYGOSITY; HUMAN; JAPAN; LETTER; PHENOTYPIC VARIATION; PRESCRIPTION; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ANTICOAGULANTS; APOLIPOPROTEINS E; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTERNATIONAL NORMALIZED RATIO; MIXED FUNCTION OXYGENASES; POLYMORPHISM, GENETIC; REGRESSION ANALYSIS; WARFARIN;

EID: 33749489633     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-006-0173-4     Document Type: Letter

References (12)

1. Shikata E, Ieiri I, Ishiguro S, Aono H, Inoue K, Koide T (2004) Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gammaglutamyl carboxylase) gene variants with warfarin sensitivity. Blood 103:2630-2635
2. Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hortnagel K, Pelz HJ (2004) Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427:537-541
3. D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V (2005) A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105:645-649
4. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL (2005) Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352:2285-2293
5. Bodin L, Verstuyft C, Tregouet DA, Robert A, Dubert L, Funck-Brentano C (2005) Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 106:135-140
6. Mushiroda T, Ohnishi Y, Saito S, Takahashi A, Kikuchi Y, Saito S, Shimomura H, Wanibuchi Y, Suzuki T, Kamatani N, Nakamura Y (2006) Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients. J Hum Genet 51:249-253
7. Kohnke H, Sorlin K, Granath G, Wadelius M (2005) Warfarin dose related to apolipoprotein E (APOE) genotype. Eur J Clin Pharmacol 5-6:381-388
8. Takahashi H, Kashima T, Kimura S, Muramoto N, Nakahata H, Kubo S, Shimoyama Y, Kajiwara M, Echizen H (1997) Determination of unbound warfarin enantiomers in human plasma and 7-hydroxywarfarin in human urine by chiral stationary-phase liquid chromatography with ultraviolet or fluorescence and on-line circular dichroism detection. J Chromatogr B Biomed Sci 701:71-80
9. Hixson JE, Vernier DT (1990) Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 31:545-548
10. Gotoh N, Kuroiwa S, Kikuchi T, Arai J, Arai S, Yoshida N (2004) Apolipoprotein E polymorphisms in Japanese patients with polypoidal choroidal vasculopathy and exudative age-related macular degeneration. Am J Ophthalmol 138:567-573
11. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106:2329-2333
12. Takahashi H, Wilkinson GR, Nutescu EA, Morita T, Ritchie MD, Scordo MG, Pengo V, Barban M, Padrini R, Ieiri I, Otsubo K, Kashima T, Kimura S, Kijima S, Echizen H (2006) Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics 16:101-110